- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03599284
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
September 19, 2019 updated by: Jiangsu vcare pharmaceutical technology co., LTD
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel in Patients With Coronary Atherosclerotic Heart Disease and Planned Percutaneous Coronary Intervention: a Multi-center, Randomized, Double-blind, Triple-dummy , Parallel-controlled, Dose-exploration Phase II Trial
This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled, dose-exploration phase II trial.
Patients with coronary atherosclerotic heart disease and planned percutaneous coronary intervention (PCI) will be randomized after informed consent, in a 1:1:1:1 ratio to the following treatment groups: Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days; Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days; Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days; Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days.
The primary purpose of this trial is to evaluate the efficacy, safety of vicagrel antiplatelet therapy and explore dose in patients with coronary atherosclerotic heart disease during and after PCI compared with clopidogrel.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
279
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100029
- China-Japan Friendship Hospital
-
Beijing, China, 100032
- Peking Union Medical College Hospital
-
Tianjin, China, 300121
- Tianjin People's Hospital
-
Tianjing, China, 300052
- Tianjin Medical University General Hospital
-
-
Anhui
-
Bengbu, Anhui, China, 233004
- First Affiliated Hospital Bengbu Medical College
-
-
Beijing
-
Beijing, Beijing, China, 100029
- Beijing Anzhen Hospital, Capital Medical Universily
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510030
- Guangdong General Hospital
-
Guangzhou, Guangdong, China, 510080
- First Affiliated Hospital of Zhongshan University
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050100
- First Hospital of Hebei Medical University
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Wuhan Asia Heart Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Xiangya Hospital of Central South University
-
Changsha, Hunan, China, 410004
- Changsha Central Hospital
-
Changsha, Hunan, China, 410011
- Second Xiangya Hospital of Central South University
-
Changsha, Hunan, China, 410013
- Third Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Affiliated Drum Tower Hospital of Nanjing University Medical School
-
Nanjing, Jiangsu, China, 210009
- Zhongda Hospital of Southeast University
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Jiangxi Provincial People's Hospital
-
-
Jilin
-
Changchun, Jilin, China, 130021
- First Hospital of Jilin University
-
-
Jinin
-
Changchun, Jinin, China, 130041
- Second Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, China, 110015
- the General Hospital of Shenyang Military Region of The Chinese People's Liberation Army(The General Hospital of Shenyang Military)
-
Shenyang, Liaoning, China, 110015
- The People's Hospital of Liaoning Province
-
Shenyang, Liaoning, China, 110134
- Shengjing Hospital of China Medical University
-
-
Qinghai
-
Xining, Qinghai, China, 810007
- Qinghai Provincial People's Hospital
-
-
Shanxi
-
Yuncheng, Shanxi, China, 044000
- Yuncheng Central Hospital
-
-
Sichuan
-
Luzhou, Sichuan, China, 646000
- Affiliated Hospital of Southwest Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Second Affiliated Hospital of Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, China, 310020
- Sir Run Run Shaw Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female aged 18-75.
- Weight ≥ 50 kg
- Patients with coronary atherosclerotic heart disease diagnosed clinically and planned percutaneous coronary intervention
- Patients with ability and willingness to sign informed consent and adherence to trial protocol.
Exclusion Criteria:
- Hemorrhagic symptoms (such as hematemesis, melena, severe or recurrent epistaxis, hemoptysis, marked hematuria, gastrointestinal bleeding, or intracranial hemorrhage), or suspected vascular malformations (such as aneurysms), or abnormal bleeding history (such as abnormal hemorrhage attributed to tooth extraction), himself or his immediate family with coagulation or bleeding disorders (such as hemophilia);
- Non-ST-segment elevation acute coronary syndrome (<2h emergency PCI), or ST-segment elevation myocardial infarction within 7 days;
- Patients with suspected aortic dissection;
- Patients with negative coronary Computed Tomography angiography(CTA)(coronary CTA depending on investigator);
- Patients with severe disease and life expectancy <1 year;
- Patients with acute peptic ulcer;
- History of hemorrhagic stroke or history of ischemic stroke within 6 months before screening and a definite diagnosis of structural abnormalities in the central nervous system;
- Patients with uncontrolled high blood pressure (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg) after drug treatment during screening;
- One of the following conditions: cardiogenic shock, chronic congestive heart with failure New York Heart Association (NYHA) grade ≥ III grade or left ventricular ejection fraction determined by echocardiography < 35%, hypotension (systolic pressure < 90 mmHg and or diastolic pressure < 60 mmHg), severe arrhythmias (including high-degree atrioventricular block, sick sinus syndrome, persistent ventricular tachycardia), severe pulmonary insufficiency, pulmonary embolism, and hepatic insufficiency (ALT or AST caused by non-cardiac diseases exceeding the upper limit of normal by more than 3 times), severe renal insufficiency (eGFR < 30 ml/min), cirrhosis;
- Patients Received P2Y12 receptor antagonist and Ⅱb/IIIa receptor inhibitor, oral anticoagulant (warfarin, rivaroxaban, dabigatran, etc.) within 14 days before screening;
- Prolonged cardiopulmonary resuscitation (more than 10 minutes) or severe trauma within 2 weeks before screening;
- Patients plan to undergo another surgery within 1 month after participating in this trial,or plan to undergo PCI procedure performed several times during the test (except for the end of the safety follow-up);
- History of severe allergies, non-allergic drug reactions or allergies to 2 or more drugs (including contrast agents), or known allergies to the similar drugs (clopidogrel, ticagrelor) as the study drug or contraindication of aspirin;
- Patients with mental disorders or alcohol dependence;
- Patients being receiving any experimental medicine or experimental medical devices;
- Prothrombin time (PT)> 1.3 times the upper limit of normal or international normalized ratio (INR)> 2.0;
- Platelet count (PLT) < 100×10^9/L or > 600×10^9/L;
- Hemoglobin < 10g/dL;
- Patients who cannot tolerate dual antiplatelet therapy for 28 days;
- Female of reproductive age with positive blood pregnancy test;
- Female with gestational intention or in lactation;
- Other unsuitable conditions considered by investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group 1
Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days
|
Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
|
Experimental: Experimental group 2
Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days
|
Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
|
Experimental: Experimental group 3
Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days
|
Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
|
Active Comparator: Control group
Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days
|
Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inhibition of platelet aggregation
Time Frame: 28 days after treatment
|
Inhibition of platelet aggregation will be assessed by Verifynow System
|
28 days after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 30, 2018
Primary Completion (Actual)
June 11, 2019
Study Completion (Actual)
July 28, 2019
Study Registration Dates
First Submitted
July 9, 2018
First Submitted That Met QC Criteria
July 23, 2018
First Posted (Actual)
July 26, 2018
Study Record Updates
Last Update Posted (Actual)
September 23, 2019
Last Update Submitted That Met QC Criteria
September 19, 2019
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Clopidogrel
Other Study ID Numbers
- VCP1-Ⅱ-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Vicagrel 5mg
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedAcute Coronary SyndromeChina
-
Jiangsu vcare pharmaceutical technology co., LTDCompleted
-
Eisai Co., Ltd.Completed
-
University of EdinburghNHS LothianCompleted
-
Vigonvita Life SciencesCompletedErectile DysfunctionChina
-
Dong-A ST Co., Ltd.CompletedThe Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis PatientsHemodialysis PatientsKorea, Republic of
-
Yuhan CorporationActive, not recruitingHypertension | HypercholesterolemiaKorea, Republic of
-
vTv TherapeuticsTerminatedAlzheimer's DiseaseUnited States, Canada
-
Bambino Gesù Hospital and Research InstituteMinistero della Salute, ItalyUnknownDilated Cardiomyopathy | Acute Heart FailureItaly
-
Chong Kun Dang PharmaceuticalCompleted